Vibe Bio

Vibe Bio is a US-based platform at vibebio.com with a LinkedIn presence, positioned at the intersection of biotech and patient-community-driven drug development for rare and neglected diseases. The platform is more accurately described as an operating company combining patient communities with therapeutic development capital and partnerships rather than a traditional fund, which means founders engaging with Vibe Bio should expect a strategic and operational collaboration model rather than a passive equity check. For healthcare AI founders, Vibe Bio is most relevant if your company is directly applicable to rare disease drug discovery, patient community engagement infrastructure, or AI-native target identification and trial recruitment for under-served indications. AI-driven diagnostic tools for rare diseases, natural history data platforms, and computational biology specifically scoped to small-population conditions could find genuine strategic fit. Generalist healthcare AI software, US payer-facing SaaS, and provider workflow tools without a rare disease angle are not the right fit. Check sizes are difficult to characterize given the operating-company structure, but engagements typically combine equity, partnership, and milestone-based capital rather than clean priced rounds. Geographic preference is US-anchored with global reach for therapeutic programs. Best entry path is a direct outreach through the website, supplemented by a LinkedIn message to the founding team with a focused articulation of how your company specifically advances rare disease drug development. Founders without a rare disease thesis should redirect their attention to traditional biotech and digital health investors rather than forcing a fit here.